A high TP53 mutation burden is a strong predictor of primary refractory mantle cell lymphoma
Jazyk angličtina Země Anglie, Velká Británie Médium print-electronic
Typ dokumentu dopisy, práce podpořená grantem
Grantová podpora
PROGRES Q26/LF1
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
PROGRES Q28/LF1
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
IGA_LF_2020_002
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
IGA_LF_2020_016
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
MH CZ - DRO (FNOL, 00098892)
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
AZV16-32339A
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
AZV16-31092A
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
RVO-VFN64165
Ministry of Health of the Czech Republic, and the Ministry of Education, Youth and Sports
PubMed
32862455
DOI
10.1111/bjh.17063
Knihovny.cz E-zdroje
- Klíčová slova
- TP53 aberration, chemoresistance, mantle cell lymphoma, mutation burden,
- MeSH
- cyklofosfamid aplikace a dávkování MeSH
- dospělí MeSH
- doxorubicin aplikace a dávkování MeSH
- lidé středního věku MeSH
- lidé MeSH
- lymfom z plášťových buněk * farmakoterapie genetika mortalita MeSH
- míra přežití MeSH
- mutace * MeSH
- nádorový supresorový protein p53 genetika MeSH
- prednison aplikace a dávkování MeSH
- přežití bez známek nemoci MeSH
- protokoly protinádorové kombinované chemoterapie aplikace a dávkování MeSH
- retrospektivní studie MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- vinkristin aplikace a dávkování MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- dopisy MeSH
- práce podpořená grantem MeSH
- Názvy látek
- cyklofosfamid MeSH
- doxorubicin MeSH
- nádorový supresorový protein p53 MeSH
- prednison MeSH
- TP53 protein, human MeSH Prohlížeč
- vinkristin MeSH
Zobrazit více v PubMed
Hoster E, Klapper W, Hermine O, Kluin-Nelemans HC, Walewski J, van Hoof A, et al. Confirmation of the mantle-cell lymphoma international prognostic index in randomized trials of the European mantle-cell lymphoma network. J Clin Oncol. 2014;32:1338-46.
Klener P. Advances in molecular biology and targeted therapy of mantle cell lymphoma. Int J Mol Sci. 2019;20:4417.
Eskelund CW, Dahl C, Hansen JW, Westman M, Kolstad A, Pedersen LB, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017;130:1903-10.
Delfau-Larue M-H, Klapper W, Berger F, Jardin F, Briere J, Salles G, et al. High-dose cytarabine does not overcome the adverse prognostic value of CDKN2A and TP53 deletions in mantle cell lymphoma. Blood. 2015;126:604-11.
Obr A, Procházka V, Jirkuvová A, Urbánková H, Kriegova E, Schneiderová P, et al. TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:762-8.
Aukema SM, Hoster E, Rosenwald A, Canoni D, Delfau-Larue MH, Rymkiewicz G, et al. Expression of TP53 is associated with the outcome of MCL independent of MIPI and Ki-67 in trials of the European MCL Network. Blood. 2018;131:417-20.
Di Agostino S, Fontemaggi G, Strano S, Blandino G, D'Orazi G. Targeting mutant p53 in cancer: the latest insights. J Exp Clin Cancer Res. 2019;38:290.
Lin RJ, Ho C, Hilden PD, Barker JN, Giralt SA, Hamlin PA, et al. Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP 53 alterations. Br J Haematol. 2019;184:1006-10.
Hanna KS, Campbell M, Husak A, Sturm S. The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma. J Oncol Pharm Pract. 2020;26:1190-9.
